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Abstract The activation of the matrix metalloproteinase
progelatinase A (MMP-2) has been of keen interest because an
increase in MMP-2 activity has been implicated in disease states
such as cancer and atherosclerosis. Activation of MMP-2 occurs
on the surface of specific cell types in two steps. In the first step,
primary cleavage of MMP-2 by a membrane-type matrix
metalloproteinase generates an intermediate. A secondary
cleavage and activation of the intermediate is thought to occur
autocatalytically. Previous studies have shown that thrombin can
also activate progelatinase A in the presence of endothelial cells.
We show that this cell-dependent mechanism of MMP-2
activation also occurs with THP-1 cells and involves binding of
thrombin to thrombomodulin present on the cell surface and
generation of the anti-coagulant protein, activated protein C. We
demonstrate that activated protein C is directly responsible for
activation and cleavage of the gelatinase A intermediate. This
work contributes new mechanistic insights into the activation of
MMP-2 and provides a novel link between matrix metallopro-
teinase activation and anti-coagulation. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Matrix metalloproteinases (MMPs) are a class of zinc-uti-
lizing proteolytic enzymes that function to degrade extracellu-
lar matrix components. These proteins are present in healthy
individuals and play central roles in wound healing and dur-
ing pregnancy [1,2] ; however, overexpression and activation
of MMPs or underexpression of the speci¢c inhibitors of met-
alloproteinases (TIMPs) can contribute to diseases such as
metastasis [3,4] and atherosclerosis [5,6]. Understanding the
mechanisms by which these enzymes are generated and acti-
vated is therefore of signi¢cant interest.
Activation of MMPs requires cleavage of a propeptide that
blocks the active site cleft in an event that comprises an im-
portant feature of MMP regulation. This cleavage results in a
conformational change that disrupts a cysteine^zinc interac-
tion (the ‘cysteine switch’), allowing the enzyme to become
active [7]. The activation of progelatinase A (MMP-2) is par-
ticularly unique among the MMP family. Progelatinase A is
not cleaved by elastase, trypsin, stromelysin, and several other
endopeptidases that have been shown to activate related
MMPs such as progelatinase B, procollagenase, and prostro-
melysin [8]. In addition, progelatinase A is produced consti-
tutively in relatively high concentrations by many cell types
and is a normal component of human blood plasma [9]. The
activation of progelatinase A is therefore particularly critical
in the control of this enzyme’s activity.
There is now strong evidence that the activation of proge-
latinase A can be accomplished through a membrane-associ-
ated mechanism. The interaction of progelatinase A with an
intrinsic membrane MMP, MT1-MMP, has been shown to
facilitate the conversion of this enzyme to an active form
[10,11]. In an interaction dependent upon the presence of
TIMP-2, MT1-MMP cleaves progelatinase A, generating a
64 kDa inactive intermediate. A process believed to occur
autocatalytically that removes an additional 43 amino acids
and generates the fully active enzyme [10] follows this cleav-
age.
Recently, Zucker et al. reported that thrombin can activate
progelatinase A in a process dependent upon the presence of
endothelial cells, but not involving the thrombin receptor [14].
Thrombin is a serine protease that plays a central role in
blood coagulation [13]. Thrombin activity contributes to the
activation of platelets, the formation of ¢brin from ¢brinogen,
and the activation of various profactors and proenzymes in
the coagulation cascade. The binding of thrombin to the en-
dothelial cell membrane protein thrombomodulin, however,
dramatically alters the substrate speci¢city of thrombin. The
ability of thrombin to cleave ¢brinogen and to activate plate-
lets and other procoagulant factors is inhibited, while its abil-
ity to activate protein C is enhanced greatly. Activated protein
C, in turn, inactivates coagulation factors Va and VIIIa and
stimulates ¢brinolysis [14]. Based on the reported requirement
of endothelial cells for the activation of progelatinase A by
thrombin and because this mechanism occurs independently
of the thrombin receptor [12], we determined whether throm-
bomodulin conferred on thrombin the ability to activate
progelatinase A. We demonstrate here that thrombomodulin
and thrombin, in the presence of serum, activate progelatinase
A and that activated protein C alone can convert the 64 kDa
gelatinase A intermediate to the fully active form. These
results are the ¢rst such evidence for the involvement of
activated protein C in the activation of gelatinase A and pro-
vide a novel link between anti-coagulation and MMP activa-
tion.
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2. Materials and methods
2.1. Zymography
Zymography was performed according to previously published
methods [15]. Brie£y, samples were electrophoresed on a 10% Tris^
glycine polyacrylamide electrophoresis gel with 0.1% gelatin as a
substrate. Precast zymogram gels were run at 125 V for 90 min and
were then incubated under the following conditions (room temper-
ature unless speci¢ed): 30 min in renaturing bu¡er (2.5% w/v Triton
X-100), 30 min in developing bu¡er (0.1 M Tris base, 0.4 M Tris^
HCl, 67 mM CaCl2, 0.2% w/v Brij 35), and 18^20 h in developing
bu¡er at 37‡C. Gels were stained according to the method of Leber
and Balkwill [16]. Brie£y, gels were rinsed with water and then stained
in a solution containing 30% methanol, 10% glacial acetic acid, and
0.02% stain derived from PhastBlue tablets (Pharmacia, Uppsala,
Sweden) for 2^4 h. Gels were then rinsed with distilled water for
15 min, soaked in drying solution (30% ethanol and 5% glycerol)
for 15 min, and dried on cellophane sheets overnight.
2.2. Cell culture
THP-1 cells were obtained from the American Type Culture Col-
lection (Rockville, MD, USA) [17]. The cells were maintained between
1U105 and 4U105 cells/ml in RPMI 1640 medium (Sigma, St. Louis,
MO, USA), with 10% fetal bovine serum (FBS) (Hyclone Laborato-
ries, Logan, UT, USA), 100 U/ml penicillin, 100 Wg/ml streptomycin,
2 mM L-glutamine (Gibco Laboratories, Gaithersburg, MD, USA),
and 0.02 mM 2-mercaptoethanol (Sigma).
Human endothelial cells were isolated from the veins of discarded
umbilical cords. The cells were isolated by collagenase digestion as
previously described [18] and maintained in a medium composed of
M-199 medium, 15% FBS, 0.1% endothelial cell growth supplement
prepared from bovine hypothalami [19], and antibiotics. Cultures were
not used beyond the sixth passage.
2.3. Enzymatic reactions
All enzymatic reactions were performed in either 100 Wl reaction
bu¡er (20 mM Tris^Cl, 100 mM NaCl, 10 mM CaCl2, and 10 WM
ZnCl2, pH 7.5) or 250 Wl RPMI 1640 with 1% FBS in the presence of
THP-1 cells or HUVEC at a concentration of 1U105 cells/ml. Reac-
tions were carried out for 48 h at 37‡C.
The activation of progelatinase B as a positive control was accom-
plished by incubation of the enzyme in 0.05 M borate (pH 9.0) con-
taining 0.01 mM ZnCl2, 5 mM CaCl2, and 0.5 mM 4-aminophenyl
mercuric acetate for 2 h at 37‡C. Human recombinant progelatinase A
and progelatinase B were from Calbiochem (San Diego, CA, USA),
rabbit lung thrombomodulin and human thrombin were from Hae-
matologic Technologies Inc. (Essex Junction, VT, USA), and the un-
activated and activated protein C were from Sigma and Haematologic
Technologies Inc.
3. Results
3.1. Thrombin^thrombomodulin activation of progelatinase A
We determined the e¡ect of thrombin on the activation of
progelatinase A in the presence and absence of HUVEC and
THP-1 cells, cell types also known to express thrombomodu-
lin and cells actively involved in the acute in£ammatory and
atherogenesis processes. Initial studies examined the activa-
tion of progelatinase A in the presence of thrombin and en-
dothelial cells. Fig. 1 presents results con¢rming that throm-
bin and endothelial cells convert the progelatinase A into the
active gelatinase A (compare lane 2 with no thrombin to lane
3 containing thrombin). Almost all of the activity that was
associated with the 64 kDa intermediate has now been con-
verted to the fully active state. Similarly, as shown in Fig. 2,
thrombin in the presence of THP-1 cells and 1% FBS was able
to activate progelatinase A (compare lanes 2 and 3). An in-
crease in the fully active, 62 kDa gelatinase A was balanced
by a corresponding decrease in the 72 kDa progelatinase A
and disappearance of the 64 kDa intermediate. However, in
the presence of 1% FBS alone, thrombin was unable to acti-
vate progelatinase A (lane 5), indicating that the THP-1 cells
were contributing an essential component for thrombin-medi-
Fig. 1. E¡ect of thrombin on the activation of progelatinase A in
the presence of endothelial cells. Progelatinase A (5 nM) was incu-
bated with thrombin (50 nM) in the presence of 1U105 HUVEC
and 1% FBS. After 48 h at 37‡C, reaction mixes were subjected to
zymography. Shown is a representative zymogram of reactions con-
ducted with progelatinase A alone (lane 1), HUVEC and progelati-
nase A (lane 2) and HUVEC, progelatinase A and thrombin (lane
3). The top band represents the 72 kDa progelatinase A, and the
bottom two bands the 64 kDa intermediate and the 62 kDa fully
active enzyme.
Fig. 2. E¡ect of thrombin and thrombomodulin on the activation of progelatinase A in THP-1 cells. Progelatinase A (pro-gel A, 5 nM) was in-
cubated in the presence of thrombin (T, 50 nM) þ thrombomodulin (TM, 50 nM) in the presence of 1U105 THP-1 cells and 1% FBS, in 1%
FBS alone, or in reaction bu¡er at 37‡C. After 48 h, reaction mixes were subjected to zymography. Shown are representative zymogram gels of
reactions conducted in the presence of THP-1 cells and 1% FBS (lanes 1^4), in 1% FBS alone (lanes 5 and 6), or in reaction bu¡er (lanes 7^
10). The top band represents the 72 kDa progelatinase A, and the bottom two bands the 64 kDa intermediate and the 62 kDa fully active en-
zyme.
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ated progelatinase A activation. The component was not a
secreted factor as THP-1 cell conditioned media failed to me-
diate the progelatinase A activation by thrombin (data not
shown). To determine whether or not thrombomodulin was
responsible for thrombin-stimulated progelatinase A activa-
tion, mixtures of rabbit lung thrombomodulin were incubated
with thrombin and progelatinase A. Although it is unclear
whether the addition of thrombomodulin changed the proge-
latinase A activation in the presence of THP-1 cells (Fig. 2,
lane 4), the co-factor protein did facilitate progelatinase A
activation by thrombin in the absence of THP-1 cells (Fig.
2, lane 6). The presence of 1% FBS was required for this
activation, as shown by the ¢nding that the combination of
thrombin and thrombomodulin had no e¡ect on progelatinase
A when the reaction was performed in reaction bu¡er alone
(Fig. 2, lane 10).
3.2. Protein C activation of progelatinase A
The ability of thrombin and thrombomodulin to activate
progelatinase A in the presence, but not the absence, of
FBS indicated that there was an additional molecule(s)
present in serum that was required for thrombin-mediated
activation of progelatinase A. We therefore tested the ability
of protein C, a known substrate for the thrombin^thrombo-
modulin complex, to substitute for the 1% serum in the acti-
vation of progelatinase A. As shown in Fig. 3, the addition of
increasing concentrations of protein C in the presence of
thrombin and thrombomodulin led to an increase in active
gelatinase A in reaction bu¡er alone, indicating that activa-
tion of protein C by thrombin and thrombomodulin is in-
volved in the activation of progelatinase A.
To con¢rm that activated protein C can act directly upon
progelatinase A, the e¡ect of activated protein C on progela-
tinase A was studied. As shown in Fig. 4, activated protein C
enhanced formation of active gelatinase A in the presence of
THP-1 cells and 1% FBS, and in reaction bu¡er alone. Acti-
vated protein C was therefore concluded to act upon gelati-
nase A directly. Here, the increase in active gelatinase A was
due to the conversion of the 64 kDa intermediate to the ¢nal
product while the amount of the 72 kDa progelatinase re-
mained unchanged.
3.3. Activated protein C e¡ects on progelatinase B
Plasmin is a serine protease that has previously also been
shown to mediate the conversion of the 64 kDa gelatinase A
Fig. 3. E¡ect of thrombin, thrombomodulin, and protein C on the
activation of progelatinase A. Progelatinase A (pro-gel A, 5 nM)
was incubated in the presence of thrombin (T, 50 nM), thrombomo-
dulin (TM, 50 nM), and increasing concentrations (nM) of protein
C in reaction bu¡er for 48 h at 37‡C. Shown is a representative zy-
mogram gel of reaction mixtures after incubation. The top band
represents the 72 kDa progelatinase A, and the bottom two bands
represent the 64 kDa intermediate and the 62 kDa fully active en-
zyme.
Fig. 4. E¡ect of activated protein C on the activation of progelati-
nase A. Increasing concentrations of activated protein C were added
to 5 nM progelatinase A in the presence of THP-1 cells and 1%
FBS or in reaction bu¡er alone for 48 h at 37‡C. Shown are repre-
sentative zymogram gels of reactions conducted in the presence of
THP-1 cells and 1% FBS, or in reaction bu¡er. The top band repre-
sents the 72 kDa progelatinase A, and the bottom two bands repre-
sent the 64 kDa intermediate and the 62 kDa fully active enzyme.
Fig. 5. E¡ect of activated protein C on the activation of gelatinase
B. Shown is a representative zymogram depicting increasing concen-
trations (nM) of activated protein C (APC) added to progelatinase
B (pro-gel B, 3 nM) in reaction bu¡er for 48 h at 37‡C (lanes 3^5).
Lane 1 represents unactivated gelatinase B, and lane 2, a positive
control lane depicting fully active gelatinase B produced by treating
progelatinase B with 0.5 mM 4-aminophenyl mercuric acetate
(APMA) for 2 h at 37‡C.
Fig. 6. E¡ect of protein C inhibitor on the activation of gelatinase
A by activated protein C. Shown is a representative zymogram de-
picting increasing concentrations (nM) of protein C inhibitor (PCI)
added to activated protein C (APC, 500 nM) and progelatinase A
(pro-gel A, 5 nM) in reaction bu¡er for 48 h at 37‡C. The top
band represents the 72 kDa progelatinase A, and the bottom two
bands represent the 64 kDa intermediate and the 62 kDa fully ac-
tive enzyme.
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intermediate and gelatinase B to the fully active forms [20]. As
activated protein C and plasmin have similar e¡ects on pro-
gelatinase A, we tested whether activated protein C was also
able to activate progelatinase B. Increasing amounts of acti-
vated protein C were added to 3 nM progelatinase B in re-
action bu¡er. As shown in Fig. 5, up to 600 nM of activated
protein C had no e¡ect on progelatinase B.
To rule out the presence of contaminating plasmin or other
potential protease activity in the activated protein C prepara-
tions, the e¡ect of protein C inhibitor on activation of gelat-
inase A was examined. As shown in Fig. 6, increasing the
concentration of protein C inhibitor to 500 nM e¡ectively
eliminated the activation of gelatinase A, strongly indicating
that activated protein C is the enzyme responsible for this
activation.
4. Discussion
We demonstrate here that protein C, activated by thrombin
and thrombomodulin, can also function to facilitate the acti-
vation of progelatinase A by converting the 64 kDa intermedi-
ate to the fully active 62 kDa form. These results demonstrate
an important link between the anti-coagulant properties of
thrombin and matrix turnover through the activation of pro-
gelatinase A. Baramova et al. have shown that the ¢brinolytic
protease, plasmin, can also cleave the gelatinase A intermedi-
ate to the active product in the presence of HT1080 cells [20].
In these studies, like those here, plasmin cannot initiate pro-
gelatinase processing, but can convert the 64 kDa intermedi-
ate to the mature, active form. It is interesting to note that
both of these mechanisms are involved in anti-coagulation,
suggesting that the activation of progelatinase A may play
an important role in this process as well ; however, the acti-
vation of a similar metalloproteinase, gelatinase B, appears
speci¢c to plasmin, as activated protein C was unable to acti-
vate this enzyme.
The di¡erences we observed in the activation of progelati-
nase A between the thrombin/THP-1 and endothelial cell ac-
tivation and activated protein C suggest that there is more to
the ability of thrombin to activate gelatinase A than just the
activation of protein C. Whereas the thrombin/THP-1 cell
activation results in a conversion of the 72 kDa progelatinase
enzyme to the active 62 kDa form, activated protein C only
facilitates the conversion of the 64 kDa intermediate to the 62
kDa protein. The MT-MMP proteins are known to be able to
process the 72 kDa proenzyme to the 64 kDa intermediate
and it may be that on the cell surface, thrombomodulin co-
ordinates with one of these proteins during progelatinase A
activation. Although we have no direct evidence to support
this conclusion, a similar mechanism of coordination has been
suggested for plasmin [20].
Our results showing that thrombin alone is insu⁄cient to
activate the 72 kDa progelatinase A or the 64 kDa intermedi-
ate are in contrast with those of Galis et al. who reported that
thrombin alone can activate progelatinase A [21]. The reaction
conditions of Galis et al., however, included the presence of
smooth muscle cell conditioned medium and serum. The dif-
ferences between the results are thought to be due to the
presence of serum containing protein C. It is also interesting
to note that Galis et al. reported that thrombin can activate
progelatinase A in the presence of cultured smooth muscle
cells, as cultured smooth muscle cells have been shown to
express thrombomodulin [22]. As the present experiments
show, thrombin activated progelatinase A in the presence of
THP-1 and endothelial cells, both of which express thrombo-
modulin on their surfaces.
Together, the results help to clarify the role of thrombin in
the activation of progelatinase A and provide the ¢rst evi-
dence for the involvement of activated protein C in metal-
loproteinase processing. Furthermore, these studies provide
additional evidence that the intermediate to active conversion
of gelatinase A may not necessarily occur autocatalytically as
has been suggested, but may be accomplished by plasmin and
activated protein C. Further clari¢cation of these processes
may in turn aid in the development of therapies and protocols
for the treatment of diseases in which these cellular events run
awry.
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